## TABLE OLIVES CONTAINING PROBIOTIC MICROORGANISMS

#### Field of the invention

5

10

15

20

25

The present invention relates to probiotic food products, i.e. food products containing microorganisms having a beneficial effect on health, in particular on the gastrointestinal tract.

### Background of the invention

Probiotic food products are in general fermented foods containing an amount of viable and active microorganisms large enough to reach the intestine and exert an equilibrating action on the intestinal microflora.

Intake of probiotics stimulates the growth of beneficial microorganisms, reduces the amount of pathogens and strengthens the body's natural defences. It is acknowledged that probiotic bacteria, in particular lactobacilli and bifidobacteria, help to maintain the equilibrium of the intestinal flora (Salminen S., et al. Int. Dairy J. 8:563-572, 1998; Saarela M., L. et al., Int. J. Food Microbiol. 2002, 78:99-117) and inhibit pathogens (Drago L., M. R. et al., FEMS Microbiol. Letters, 1997, 153:455-463 and Cross M. L. FEMS Immunol. Med. Microbiol. 2002, 34:245-253), thus lowering the risk of gastro-intestinal diseases. In fact, when the intestinal microflora is altered, administration of probiotic bacteria not only re-establishes its normal equilibrium, but also improves the microbial balance and properties of the endogenous flora. The role of probiotics in the prevention of food allergies and intolerances is also under study (Isolauri E., et al., Am. J. Clin. Nutr. 2001, 73 (suppl.): 444s-450s; Jahreis G., et al. Food Res. Int. 2002, 35:133-138).

Probiotic bacteria are introduced in food products for human nutrition, especially in fermented milk, for example in yogurt. One of the problems related to the production of probiotic foods is the influence of production

technologies on strains properties, in particular cell viability, integrity, and population stability (Mattila-Sandholm T., et al. Int. Dairy, 2002 J. 12:173-182). Liquid and frozen cultures were largely used in the past, but their production, transport and storage costs are high. Lyophilized cultures are presently widespread, but cells are often damaged and cannot be stored for a long time. In fact lyophilised cells survive in anaerobiosis and viability is restored by rehydration. This treatment not only does not ensure survival of all the cells, but the survived ones may also be metabolically altered and not withstand gastric acidity. Concentrated monodose cell cultures are also widespread. In this case the greatest difficulty is to reach high cell concentrations, i.e. to about  $10^{10}$  (UFC)/g. Therefore, most of the presently available probiotics are of animal origin, in particular dairy products, such as yogurt, cheese, desserts, ice-creams. However, dairy product consumption may be limited due to allergies or intolerances to milk and derivatives thereof. Also known is the difficulty of introducing bifidobacteria - largely used in probiotics - in fermented milk products, due to their strain-related sensibility to milk-fermenting bacteria, pH, temperature and oxygen concentration (Gobbetti M. et al. J. Dairy Sci. 1998, 81:37-47).

5

10

15

20

25

Probiotic dehydrated fruits have been obtained on an experimental scale by vacuum drying fruits soaked in probiotic microorganisms (Betoret N., et al. J. Food Engin. 2003, 56:273-277), while some oat-based products and fruit juices containing probiotic bacteria are already available on the market (Johansson et al. Int. J. Food Microbiol., 1998, 42:29-38).

It should also be pointed out that all the above-mentioned products must be consumed rapidly after opening.

It should therefore be advantageous to provide food products that allow to administer probiotic bacteria without causing allergies or intolerances and that can be stored for a long time after opening.

#### DETAILED DESCRIPTION OF THE INVENTION

5

10

15

20

25

The present invention relates to probiotic food products based on table olives containing probiotic bacteria.

In a first embodiment, the food product consists of table olives whose pericarp is coated with microorganisms of the *Lactobacillus* and *Bifidobacterium* genus, in particular probiotic lactobacilli and bifidobacteria. Preferably, the lactobacilli are selected from *Lactobacillus rhamnosus* and *Lactobacillus paracasei*, while the bifidobacteria are selected from *Bifidobacterium bifidum* and *Bifidobacterium longum*. Even more preferably, the microorganisms are selected from: *Lactobacillus rhamnosus* GG ATCC53103; *L. rhamnosus* IMPC 11; *L. rhamnosus* IMPC 19; *Lactobacillus paracasei* IMPC 2.1 (deposited with the Belgian Coordinated Collections of Microorganisms, BCCM/LMG-Collection, Gent, Belgium, under accession number LMG P-22043); *Lactobacillus paracasei* IMPC 4.1; *Bifidobacterium bifidum* ATCC15696 and *Bifidobacterium longum* ATCC15708.

The olives of the invention can be prepared by keeping table olives in a suspension of the desired microorganism, at room temperature (about 25°C), thus obtaining olives on whose pericarp microorganisms adhere in amounts ranging from  $5 \times 10^5$  to  $5 \times 10^8$  UFC/gram (evaluation after 3 month storage, see tables 1 and 2).

The table olives of the invention can be either consumed as such, or used for the preparation of probiotic food products, which are a further embodiment of the invention.

The olives and probiotic foods of the invention are an effective means to treat or prevent intestinal disorders or restore the intestinal flora after antibiotic therapy.

Particularly beneficial are the olives enriched with *L. paracasei* IMPC 2.1, not only due to the marked probiotic characteristics of this microorganism, its

ability to grow both under aerobic and anaerobic conditions and adhere to the pericarp, but also due to its resistance to gastric juices and bile salts. *L. paracasei* IMPC 2.1 is a new microorganism and is a further embodiment of the invention.

Particularly important is also the possibility of incorporating bifidobacteria, since it is known that these microorganisms hardly grow and survive in fermented milk products.

5

10

15

20

25

The olives of the present invention and the food products containing them are particularly useful for the prevention and treatment of diseases caused by food contaminants, in gastro-intestinal diseases affecting travellers, as coadjuvants in antibiotic therapy and, more generally, in situations in which it is necessary to increase the body immune defences.

Thanks to convenient administration, storage in non-refrigerated conditions (after 90 days at room temperature the bacterial count ranges from  $1 \times 10^5$  to  $7.6 \times 10^7$  UFC per gram), as well as organoleptic properties, the olives can be consumed whenever prompt administration of probiotic bacteria is required, even by lactose-intolerant people. A further advantage is that consumption of only part of the package content (i.e. olives, not brine), provides a dose of probiotic bacteria that corresponds to that provided by yogurt or concentrated cultures.

Finally, it must also be pointed out that with respect of probiotic foods of animal or vegetal origin, wherein microorganisms are re-suspended in a liquid medium, in the case of olives the bacterial cells are immobilized, which ensures an effective, safe transport in the gastro-intestinal tract. Moreover, the binding to a product containing a large amount of fats, allows the microorganisms to resist to gastric juices.

#### EXPERIMENTAL SECTION

Example 1 - Viability of probiotic bacteria on the olive pericarp

Colonization of the pericarp of table olives and the survival of the

following strains have been evaluated: Lactobacillus rhamnosus GG ATCC53103, L. rhamnosus IMPC 11 and IMPC 19, Lactobacillus paracasei IMPC 2.1 and IMPC 4.1, Bifidobacterium bifidum ATCC15696 and Bifidobacterium longum ATCC15708.

Lactobacillus paracasei IMPC 2.1 was deposited with the Belgian Coordinated Collections of Microorganisms, BCCM/LMG-Collection, Gent, Belgio under accession number LMG P-22043.

Tests were carried out on stoned and whole black olives, previously de-bittered and processed so as to make them edible. The same tests were also carried out on fresh or semifinished green and black olives and on de-bittered and processed green olives (finished product). Strains viability was evaluated using jars containing 80 olives immersed in 280 ml of their own brine or in NaCl 4% ± fructose 0.2÷1%, pH 6.5.

Procedure. Black olives immersed in their own brine (finished product) were added with a bacterial suspension containing from  $4 \times 10^9$  to  $9 \times 10^{11}$  (UFC) of each strain. After the inoculum the olives are placed in sterile jars closed with screw-caps. Non-inoculated olives, also in jars, were used as the control. The samples were stored for 3 months at room temperature (about 25°C), thereafter 4 olives were taken from each sample at t=1, 15, 30 and 90 and submitted to bacterial count. Brine was thoroughly removed and the olives were added with 20 ml 0.85% NaCl and 0.025% Tween 80 and vigorously shaken for two hours to detach the bacteria from the pericarp. The resulting suspension was seeded on an agar substrate for the count of lactic bacteria. The results are reported in the following table.

5

10

15

20

Table 1. UFC per gram of stoned olives

strain	1 day	15 days	30 days	90 days
L. rhamnosus GG ATCC53103	$5.0 \times 10^8$	$3.5 \times 10^7$	$3.4 \times 10^{7}$	$3.2 \times 10^7$
L. rhamnosus IMPC 11	$7.0 \times 10^7$	$8.0 \times 10^{8}$	$7.5 \times 10^7$	$7.6 \times 10^7$
L. rhamnosus IMPC 19	$7.2 \times 10^7$	$8.5 \times 10^8$	$6.8 \times 10^6$	$6.9 \times 10^6$
L. paracasei IMPC 2.1	$7.6 \times 10^7$	$2.0 \times 10^9$	$7.9 \times 10^{7}$	$6.0 \times 10^6$
L. paracasei IMPC 4.1	$4.8 \times 10^7$	$5.8 \times 10^7$	$6.5 \times 10^7$	$6.8 \times 10^7$
B. bifidum ATCC 15696	$2.5 \times 10^7$	$8.0 \times 10^{7}$	$5.2 \times 10^7$	$4.3 \times 10^6$
B. longum ATCC 15708	$4.5 \times 10^6$	$2.7 \times 10^7$	$8.7 \times 10^6$	$5.2 \times 10^5$

Table 2. UFC per gram of whole olives

5

10

strain	1 day	15 days	30 days	90 days
L. rhamnosus GG ATCC53103	$1.8 \times 10^7$	$2.3 \times 10^6$	$7.6 \times 10^5$	$3.9 \times 10^6$
L. rhamnosus IMPC 11	$7.0 \times 10^6$	$1.0 \times 10^7$	$2.4 \times 10^6$	$1.5 \times 10^6$
L. rhamnosus IMPC 19	$3.5 \times 10^6$	$1.0 \times 10^{7}$	$2.5 \times 10^5$	$2.7 \times 10^5$
L. paracasei IMPC 2.1	$7.4 \times 10^6$	$3.0 \times 10^{7}$	$4.4 \times 10^{7}$	$9.0 \times 10^6$
L. paracasei IMPC 4.1	$7.1 \times 10^6$	$1.1 \times 10^{7}$	$5.4 \times 10^{7}$	$8.0 \times 10^6$
B. bifidum ATCC 15696	$1.3 \times 10^6$	$7 \times 10^6$	$3.6 \times 10^6$	$1.2 \times 10^6$
B. longum ATCC 15708	$5.0 \times 10^5$	$3.6 \times 10^6$	$3.6 \times 10^6$	$1.0 \times 10^5$

All the experiments were repeated twice and relevant variations were not observed.

The pericarp allows tight anchorage of the bacteria and ensures their slow release after intake, as demonstrated by the drastic re-suspension procedure. In particular, about 10<sup>6</sup> UFC/g were recovered from samples analysed 30 days after addition of the bacteria by vigorous stirring for 2 hours

in physiological solution added with Tween; after 3 subsequent washings (1 h each in the same conditions) about  $10^5$ ,  $10^4$  and  $10^3$  UFC/9 g still adhered to the pericarp.

Similar tenacity was observed in samples taken after 7 or 90 days from the addition of the bacteria.

# Example 2 - Selection of *Lactobacillus paracasei* IMPC 2.1 (reference strain)

Lactobacillus paracasei IMPC 2.1 was isolated from a healthy adult human subject with a bacterial population of 10<sup>7</sup> UFC/g in faeces.

## Strain genetic identification

5

10

15

20

25

Species-specific PCR with Y2/PARA primers (figure 1) was carried out as the first identification step. Y2 is the universal primer for eubacteria, while PARA is the specific primer for *L. paracasei*. IMPC 2.1 showed an amplification band of 290 bp, typical of *L. paracasei* species.

ARDRA using Sau 3AI as the restriction enzyme was carried out as a confirmation analysis; also in this case the expected restriction profiles of *L. paracasei* were obtained (Figure 2).

L. paracasei IMPC 2.1 is able to tightly adhere to pig intestinal mucus, abiotic surfaces and pericarp and is highly resistant to bile acids, as demonstrated by the following experiments.

## Adhesion to pig intestinal mucus

An *in vitro* test for adhesion to pig intestinal mucus was carried out to evaluate *in vivo* adhesion, according to the method of Schou, et al. (APMIS 1999, 107: 493-504), partially modified as follows.

96-Well plates, coated with pig mucus (Tipe II, Sigma), were seeded with a titred bacterial suspension (100 µl, PBS buffer). After incubation for 2 hrs at 37°C with rocking, the plates were washed three times with PBS and the mucus was mechanically removed from the wells, then the washings and

mucus were seeded in plates. Figure 3 reports a SEM image of L. paracasei IMPC 2.1 adhering to the mucus after three washings.

The L. paracasei strains used in the test are listed hereinbelow, together with the results of the count (percentage ratio of UFC on the mucus in the final step to UFC in the titred bacterial suspension)

- 1) IMPC 2.1 = 40%
- 2) IMPC CV1 = 37%
- 3) IMPC 4.1 = 10%
- 4) IMPC 1.3 = 40%
- 10 5) IMPC 1.5= 33%

5

- 6) IMPC 1.4= 35%
- 7) Chr.Hansen Lc1= 39%
- 8) IMPC CLV1= 38%
- 9) ATCC 10863= 18%
- 15 IMPC 2.1 is one of the strains which adhere better.

#### Resistance to bile salts

The resistance of *L. paracasei* strains was evaluated using MRS medium (De Man et al., J. Appl. Bacteriol., 1960, 23:130-135) containing Oxgall bovine bile salts at different concentrations. The first tests were carried out using 0.2, 0.3, 0.4% Oxgall: in these conditions the strain showed slightly reduced growth at increased concentrations. Growth was evaluated by measuring optical density (OD) at 600 nm.

20

Strains	MRS	0.2% Oxgall	0.3% Oxgall	0.4% Oxgall
2.1	1.847	1.678	1.739	1.570
Acti	1.942	1.587	1.314	1.043
Sal	1.942	1.674	1.583	1.451
CV1	1.853	1.640	1.518	1.312
CLV1	1.813	1.688	1.634	1.344
B21070	1.714	1.455	1.316	1.185
B21060	1.954	1.789	1.657	1.453
1.3	1.829	1.818	1.697	1.583
1.4	1.843	1.840	1.679	1.581
1.5	1.875	1.760	1.818	1.674
4.1	1.978	1.694	1.441	1.559

In the subsequent step (the bile acid) concentration was increased up to 0.7%.

Strain	MRS	0.5% Oxgall	0.6% Oxgall	0.7% Oxgall
2.1	1.458	0.792	0.178	0.095
Acti	1.548	0.139	0.061	-0.132
Sal	1.354	0.758	0.562	0.353
CV1	1.399	0.160	-0.038	-0.156
CLV1	1.313	0.322	0.176	0.055
B21070	1.435	-0.142	-0.200	-0.193
B21060	1.367	0.729	0.611	0.280
1.3	1.377	0.576	0.234	0.314
1.4	1.525	0.695	0.927	0.396
1.5	1.475	0.866	0.916	0.603
4.1	1.502	0.817	0.764	0.561

IMPC 2.1 proved one of the strains with good resistance to bile salts.

Salinity resistance

MRS medium was used to evaluate strain resistance to different NaCl concentrations. Also in this case growth was evaluated by measuring optical density (OD) at 600 nm.

Strain	MRS	0.5% NaCl	1% NaCl	2% NaCl
2.1	1.847	1.644	1.457	1.513
Acti	1.942	1.551	1.689	1.483
Sal	1.942	1.685	1.665	1.601
CV1	1.853	1.555	1.541	1.781
CLV1	1.813	1.512	1.689	1.648
B21070	1.714	1.711	1.658	1.491
B21060	1.954	1.560	1.717	1.510
1.3	1.829	1.656	1.631	1.697
1.4	1.843	1.658	1.795	1.737
1.5	1.875	1.534	1.554	1.697
4.1	1.978	1.811	1.762	1.596

Since high growth rate was observed also with 2% NaCl, tests with higher concentrations were carried out.

Strain	MRS	3% NaCl	4% NaCl	5% NaCl
2.1	1.300	1.217	1.081	0.896
Acti	1.327	1.317	1.169	1.073
Sal	1.288	1.275	1.180	0.985
CV1	1.283	1.185	1.031	0.829
CLV1	1.217	1.158	1.036	0.799
B21070	1.266	1.269	1.128	0.947
B21060	1.321	1.177	1.090	0.962
1.3	1.239	1.207	1.050	0.922
1.4	1.306	1.183	1.026	0.823
1.5	1.289	1.266	1.061	0.899
4.1	1.291	1.245	1.075	0.897

IMPC 2.1 proved to be one of the strains with better salinity resistance.

## Resistance to simulated gastric juice (UFC/ml)

5

10

Strain resistance to simulated gastric juice was evaluated using different strains cultured in MRS medium. The cultures were washed with sterile saline and added to an equal volume of simulated gastric juice (NaCl, 125mM<sup>-1</sup>; KCl 7 mM<sup>-1</sup>; NaHCO<sub>3</sub>, 45 mM<sup>-1</sup> and pepsin, 3 gr l<sup>-1</sup>), adjusting the pH to 2 with HCl. The suspensions were then incubated at room temperature under stirring (200 rev min<sup>-1</sup>) to simulate peristalsis. Aliquots were taken at time 0 and after 90 and 150 minutes and counted on MRS agar.

Strain	$T_0$	T <sub>1</sub> (90 min)	$T_2(150 \text{ min})$
2.1	44•10 <sup>6</sup>	1.22-108	2.15•107
1.4	41•10 <sup>6</sup>	4.5•107	3•10 <sup>7</sup>
B21070	17.8•10 <sup>6</sup>	2•10 <sup>7</sup>	5.8•10 <sup>7</sup>
Sal	197•10 <sup>6</sup>	1.13•108	5.2•10 <sup>7</sup>
4.1	116•10 <sup>6</sup>	1.09•108	$1.77 \cdot 10^{7}$

IMPC 2.1 proved one of the strains with better resistance to simulated gastric juice.

#### Adhesion to abiotic surfaces

Adhesion ability, necessary for the strains to colonize the intestinal mucosa, was evaluated also with a test for adhesion to abiotic surfaces (Tuomola et al., Int. J. Food Microbiol., 2000, 41:45-51). The strains were cultured in MRS medium, at 37°C for 48 hours under anaerobiosis. The cultures were then diluted 1:40 in MRS and 200 μl aliquots were seeded in 96-well polystyrene plates. After incubation for 24 hours at 37°C the wells were gently rinsed with Dulbecco's phosphate buffer (DPBS, pH 7.3), allowed to dry and added with a crystal violet solution to stain the cells. Excess of dye was washed away with ethanol-acetone (80:20 v/v), then optical density (DO) was measured with an automatic reader. On the basis of DO values, cells were divided into 4 adhesion classes: no adhesion (AC1, OD≤0.5), weak adhesion (AC2, 0.5<OD≤1.2), mean adhesion (AC3, 1.2<OD≤2.0) and strong adhesion (AC4, OD>2.0) (Table 3).

To evaluate the effect of enzymatic, physical and chemical treatment on the adhesion ability of the strains, bacterial cultures at the beginning of the stationary phase (6 hrs growth) were submitted to the said treatments at various temperatures and times, thereafter adhesion changes were evaluated. The adhesion properties are reported in the following table. The results show that the adhesion properties of the strains are generally not much altered by physical, chemical and enzymatic treatment.

Table 3. Adhesion of *L. paracasei* IMPC 2.1, compared with *L. rhamnosus* GG ATCC53103 and another *L. paracasei* strain, on an abiotic surface before and after physical, chemical and enzymatic treatment.

5

10

15

20

Strain	L. rhamnosus GG ATCC53103	L. paracasei IMPC 2.1	L.paracasei IMPC 4.1
Cultures incubated for 24 h in wells	4	4	2
Control cells (6 hrs incubation)	4	4	2
Physical treatment			
30 min/65°C	1	2	1
15 min/120°C	1	1	1
Enzymatic Treatment			
Buffer A	4	3	2
5.0 mg/ml trypsin	1	2	1
5.0 mg/ml proteinase	1	2	1
5.0 mg/ml chemotrypsin	1	2	1
Buffer B	4	3	2
5.0 mg/ml pepsin	2	3	1
Chemical Treatment			
Buffer C	4	3	2
0.05 M sodium periodate	4	3	2
0.05 M sodium iodate	4	3	2
5M LiCl	2	2	1

<sup>&</sup>lt;sup>a</sup> Adhesion Class (AC):1, OD≤0.5; 2, 0.5<OD≤1.2; 3, 1.2<OD≤2.0; 4, OD>2

## Adhesion to pericarp

Figure 4 shows anchoring and distribution of L. paracasei IMPC 2.1 on the pericarp (see also tables 1 and 2).

## Example 3 - Persistence of *L. paracasei* IMPC 2.1 in the gastro-intestinal tract

### Experiment 1

5

10

15

Two healthy adult subjects were fed for 7 days with portions of 5 (subject 1) and 10 (subject 2) olives, thoroughly drained, containing in all  $3x10^{10}$  and  $6x10^{10}$  UFC of *L. paracasei* IMPC 2.1 respectively. The composition of the intestinal flora of the subjects was monitored at the beginning (time 0) and after 7 days (t=7) of administration and after 3 days from the end of administration. At each sampling, 1 g of faeces from each subject was added with 9 ml of Amies medium, homogenized and submitted to decimal dilutions, which were plated on a 12  $\mu$ g/ml Rogosa  $\pm$  vancomycin

substrate and cultured under anaerobiosis for 48 hours at 37°C.

Table 4. Lactic populations in human subjects before and after administration of table olives added with *L. paracasei* IMPC 2.1.

	Total UFC on Rogosa + vancomycin			
	t=0	t=7 days	t=3 days after suspension	
Subject 1 fed with $3x10^{10}$ UFC/die	$2.7 \times 10^7$	$2 \times 10^9$	$4.5 \times 10^6$	
Subject 2 fed with $6x10^{10}$ UFC/die	$7.0 \times 10^4$	$3.1 \times 10^6$	$5.2 \times 10^5$	

An increase of about two logarithmic cycles in the intestinal lactic population of the two subjects was observed; an expected reduction of about 2.5 cycles in subject 1 and of about 1 cycle in subject 2 was observed after suspension of the administration.

#### **Experiment 2**

5

Two healthy adult subjects (A and B) were fed with portions of ten olives containing about 10<sup>9</sup> CFU of *L. paracasei* IMPC 2.1. The intestinal microflora of was monitored at the beginning of the experiment (t=0), after 10 days of daily consumption of the product (t=10) and 7 days from the end of administration, according to the procedure described in experiment 1. The results are reported in the following table.

The colonies isolated in both experiments were subjected to molecular identification (see Example 2), whereby it was ascertained that *L. paracasei* IMPC 2.1 was present in the two subjects and colonized the intestine.